Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

Trial Profile

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2018

At a glance

  • Drugs Dabrafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 13 Oct 2017 New trial record
    • 12 Sep 2017 Interim results (n=115) assessing real-world characteristics and treatment patterns of patients prescribed Ipilimumab, Nivolumab or Ipilimumab+Nivolumab cohort, were presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top